| Time point | Enrollment | Implant | Pre-discharge | 6-12-24 month follow-up | Implant | 6-12-24 month follow-up |
---|---|---|---|---|---|---|---|
 | Study activity | ALL patients |  | MPP group |  | Standard ICD group | |
Enrollment | Low-dose dobutamine stress echocardiography | X | Â | Â | Â | Â | Â |
Informed consent process | X | Â | Â | Â | Â | Â | |
Verification of inclusion/exclusion criteria | X | Â | Â | Â | Â | Â | |
Demographics and medical history | X | Â | Â | Â | Â | Â | |
Randomization | X | Â | Â | Â | Â | Â | |
Intervention: | MPP device implant | Â | X | Â | Â | Â | Â |
Standard ICD implant | Â | Â | Â | Â | X | Â | |
Assessment | Fluoro images and/or cine of venogram and final lead position, two projections | Â | X | Â | Â | X | Â |
Capture thresholds and signal amplitude measurements on RA and RV leads | Â | X | X | X | X | X | |
Capture thresholds and phrenic nerve stimulation occurrence at LV pacing configurations | Â | X | X | X | Â | Â | |
NYHA functional class | X | Â | Â | X | Â | X | |
QRS duration | X | Â | X | X | Â | X | |
Standard echo measurements | X | Â | Â | X | Â | X | |
Electrical delay measurements | Â | Â | X | X | Â | Â | |
QRS optimization | Â | Â | X | X | Â | Â | |
12-lead ECG during QRS optimization | Â | Â | X | X | Â | Â | |
Echo measurements and AV optimization | Â | Â | X | X | Â | Â | |
Optimal programming of the device | Â | Â | X | X | Â | Â |